10:03 AM EST - Trillium Therapeutics Inc. : Reported financial and operating results for the year ended December 31, 2017. As of December 31, 2017, Trillium had cash and cash equivalents and marketable securities, and working capital of $81.8 million and $68.9 million, respectively, compared to $50.5 million and $45.5 million, respectively at December 31, 2016. Net loss for the year ended December 31, 2017 of $45.1 million was higher than the loss of $31.7 million for the year ended December 31, 2016. Trillium Therapeutics Inc.
shares T.TRIL are trading up $0.17 at $9.82.
